Older Americans are stopping GLP-1 weight-loss drugs for four main reasons.

A January 2025 JAMA study of more than 125,000 people reported that many patients — particularly older adults — stop GLP-1 medications within a year. Reports cite side effects, rising costs and coverage limits, muscle loss concerns, and gaps in clinical follow-up as the main reasons.

Many older Americans are reported to be stopping GLP-1 weight-loss medications after starting them. The topic has drawn attention because these drugs are widely used for type 2 diabetes and weight management in older adults. A January 2025 study in JAMA, which reviewed more than 125,000 people, found high rates of discontinuation within a year. Coverage decisions and clinical questions about side effects and muscle loss have increased discussion among clinicians and patients. What was reported: - A January 2025 JAMA study of over 125,000 people found about 47% of those with type 2 diabetes and 65% of those without diabetes stopped GLP-1 drugs within a year. - Commonly reported side effects include nausea, vomiting, diarrhea, constipation, bloating, headaches, fatigue and hair thinning, and older patients may experience some effects more intensely. - Cost and changes in insurance coverage were reported as a reason people stopped when out-of-pocket prices rose substantially. - Reviews and research have noted that a portion of weight lost on these drugs can include muscle mass, which is an important consideration for older adults. - Several experts reported that individualized dosing and closer clinical follow-up can affect whether patients are able to continue treatment. Summary: Reports indicate that side effects, affordability and coverage, concerns about muscle loss, and variations in clinical management are the main reasons many older adults discontinue GLP-1 medications. This pattern may reduce the treatments' longer-term benefits for weight and related health measures. Undetermined at this time.